Literature DB >> 9520006

Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.

L Berg1, D W McKeel, J P Miller, M Storandt, E H Rubin, J C Morris, J Baty, M Coats, J Norton, A M Goate, J L Price, M Gearing, S S Mirra, A M Saunders.   

Abstract

OBJECTIVE: To study differences between subjects with Alzheimer disease (AD) and cognitively intact control subjects, with respect to brain histologic markers of AD, and the relationship of those markers in the AD group to severity of dementia, age at death, sex, and apolipoprotein E genotype.
SETTING: Washington University Alzheimer's Disease Research Center, St Louis, Mo. DESIGN AND
SUBJECTS: Consecutive neuropathologic series of 224 prospectively studied volunteer research subjects, 186 with dementia of the Alzheimer type (DAT) or "incipient" DAT and confirmed to have AD by postmortem examination and 13 cognitively intact subjects, confirmed to lack postmortem findings of AD. MAIN OUTCOME MEASURES: Brain densities (number per square millimeter) of senile plaques and neurofibrillary tangles, extent of cerebral amyloid angiopathy, cortical Lewy bodies, and apolipoprotein E genotype.
RESULTS: Neocortical neurofibrillary tangle densities were substantially correlated with dementia severity, and to a greater degree than was true for senile plaque densities. When infarcts, hemorrhages, and Parkinson disease changes coexisted with AD, neurofibrillary tangle and senile plaque densities were lower. Plaque-predominant AD was found in a greater proportion of subjects with milder than more severe dementia. Entorhinal cortical Lewy bodies were no more frequent in plaque-predominant AD than in the remaining AD cases. Increasing age at death was negatively correlated with dementia severity and densities of senile plaques and neurofibrillary tangles. The apolipoprotein E epsilon4 allele frequency was greater in AD than in control subjects but decreased with increasing age. After controlling for dementia severity, senile plaque densities were only weakly related to epsilon4 allele frequency, and only in hippocampus. However, the degree of cerebral amyloid angiopathy was clearly related to epsilon4 allele frequency. Among subjects diagnosed during life as having DAT or incipient DAT, only 7% were found to have a neuropathologic disorder other than AD causing their dementia.
CONCLUSIONS: (1) The order of the strength of relationships between densities of histologic markers and dementia severity in AD is neurofibrillary tangles greater than cored senile plaques greater than total senile plaques. (2) Advanced age at death is associated with somewhat less severe dementia and fewer senile plaques and neurofibrillary tangles. (3) Plaque-predominant AD may represent a developmental stage in AD. (4) Despite a substantial effect of apolipoprotein E epsilon4 as a risk factor for AD, on decreasing the age at AD onset, and increasing the amount of cerebral amyloid angiopathy, its effect on senile plaque densities is variable and complex, being confounded with age, dementia severity, and methodologic differences. (5) Stringent clinical diagnostic criteria for DAT, even in the very mild stage, and senile plaque-based neuropathologic criteria for AD are highly accurate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520006     DOI: 10.1001/archneur.55.3.326

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  248 in total

1.  Predictors of mortality in patients with Alzheimer's disease living in nursing homes.

Authors:  G Gambassi; F Landi; K L Lapane; A Sgadari; V Mor; R Bernabei
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

2.  Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).

Authors:  M J de Leon; A Convit; O T Wolf; C Y Tarshish; S DeSanti; H Rusinek; W Tsui; E Kandil; A J Scherer; A Roche; A Imossi; E Thorn; M Bobinski; C Caraos; P Lesbre; D Schlyer; J Poirier; B Reisberg; J Fowler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-28       Impact factor: 11.205

3.  Age-related loss of noradrenergic neurons in the brains of triple transgenic mice.

Authors:  Kebreten F Manaye; Peter R Mouton; Guang Xu; Amy Drew; De-Liang Lei; Yukti Sharma; G William Rebeck; Scott Turner
Journal:  Age (Dordr)       Date:  2011-11-30

4.  Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.

Authors:  John C Morris
Journal:  Arch Neurol       Date:  2012-06

5.  Toward a multifactorial model of Alzheimer disease.

Authors:  Martha Storandt; Denise Head; Anne M Fagan; David M Holtzman; John C Morris
Journal:  Neurobiol Aging       Date:  2012-01-20       Impact factor: 4.673

6.  Autoregulation of cerebral blood flow to changes in arterial pressure in mild Alzheimer's disease.

Authors:  Allyson R Zazulia; Tom O Videen; John C Morris; William J Powers
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

7.  Effects of healthy aging and early stage dementia of the Alzheimer's type on components of response time distributions in three attention tasks.

Authors:  Chi-Shing Tse; David A Balota; Melvin J Yap; Janet M Duchek; David P McCabe
Journal:  Neuropsychology       Date:  2010-05       Impact factor: 3.295

8.  Predicting conversion to dementia of the Alzheimer's type in a healthy control sample: the power of errors in Stroop color naming.

Authors:  David A Balota; Chi-Shing Tse; Keith A Hutchison; Daniel H Spieler; Janet M Duchek; John C Morris
Journal:  Psychol Aging       Date:  2010-03

9.  Metabolic syndrome and cognitive decline in early Alzheimer's disease and healthy older adults.

Authors:  Amber S Watts; Natalia Loskutova; Jeffrey M Burns; David K Johnson
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 10.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.